Terapevticheskii Arkhiv最新文献

筛选
英文 中文
[Prediction of the course of antibiotic-associated diarrhea caused by Clostridioides difficile based on clinical and laboratory characteristics of the disease]. [基于临床和实验室特征预测艰难梭菌引起的抗生素相关性腹泻的病程]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.203040
K D Ermolenko, T V Potapova, K V Silav, K V Zhdanov, D A Lioznov, D A Gusev
{"title":"[Prediction of the course of antibiotic-associated diarrhea caused by <i>Clostridioides difficile</i> based on clinical and laboratory characteristics of the disease].","authors":"K D Ermolenko, T V Potapova, K V Silav, K V Zhdanov, D A Lioznov, D A Gusev","doi":"10.26442/00403660.2024.11.203040","DOIUrl":"https://doi.org/10.26442/00403660.2024.11.203040","url":null,"abstract":"<p><strong>Background: </strong>The most severe complications of antibiotic use are clostridial infection (CDI) and pseudomembranous colitis (PMC). There is a need for further study of these conditions and identification of their triggers.</p><p><strong>Aim: </strong>To identify risk factors for severe forms of antibiotic-associated diarrhea caused by <i>Clostridioides difficile</i>.</p><p><strong>Materials and methods: </strong>A clinical and laboratory examination of 440 patients with CDI who were treated at Botkin Clinical Infectious Diseases Hospital was conducted. CDI was confirmed by detection of toxins A and B of <i>C. difficile</i> in feces using enzyme-linked immunosorbent assay and immunochromatography. Metronidazole (2 g/day, in patients without comorbid pathology) and vancomycin (0.5-2 g/day) were used as a starting drug for up to 14 days. Statistical processing of the obtained data was performed using the Statistica for Windows, v.10 (StatSoft, USA) program.</p><p><strong>Results: </strong>CDI was confirmed by enzyme-linked immunosorbent assay in 202 (45.91%) patients, immunochromatography - in 149 (33.86%), endoscopically - in 203 (46.14%). CDI was most frequently recorded in 2 age groups of patients: 18-30 years old - in 137 (31.14%); over 60 years old - in 205 (46.59%). CDI was characterized by a combination of colitic and intoxication syndromes. In 43 (9.77%) patients the disease resulted in death. The diagnosis of PMС was established in 61 (13.86%) people. The risks of developing PMC when prescribing antibacterial drugs decreased in the following order: fluoroquinolones, cephalosporins, macrolides, penicillins, nitrofurans and chloramphenicol. Probiotic drugs reduced the risk of developing PMC (relative risk 0.5 [0.3; 0.7]; <i>p</i>=0.002).</p><p><strong>Conclusion: </strong>PMC was characterized by a combination of diarrhea, intoxication and abdominal pain. The formation of PMC was preceded by courses of antibacterial drugs of the fluoroquinolone and cephalosporin groups, eradication therapy for <i>Helicobacter</i> infection, the use of high doses of glucocorticosteroids, as well as intestinal superinfection in patients with previous episodes of CDI.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1042-1048"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Long-COVID, severe course, with congenital bronchiectasis, Williams-Campbell syndrome. Case report]. [长期covid,重症,先天性支气管扩张,威廉姆斯-坎贝尔综合征。病例报告)。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.202997
S A Pribylov, T A Maslova, V S Pribylov, K O Leonidova, N N Pribylova, A P Kuts
{"title":"[Long-COVID, severe course, with congenital bronchiectasis, Williams-Campbell syndrome. Case report].","authors":"S A Pribylov, T A Maslova, V S Pribylov, K O Leonidova, N N Pribylova, A P Kuts","doi":"10.26442/00403660.2024.11.202997","DOIUrl":"https://doi.org/10.26442/00403660.2024.11.202997","url":null,"abstract":"<p><p>We present a clinical observation of an 18-year-old female patient with congenital bronchiectasis combined with congenital cystic degeneration of the upper lobes of both lungs, Williams-Campbell syndrome, long-COVID, severe course. The patient was treated in infectious disease department (three times), with subsequent transfer to pulmonology department of Kursk Regional Multi-Purpose Clinical Hospital from 31.01.2023 to 02.05.2023. The patient was going to have lung transplantation, registered in Shumakov Federal Research Center of Transplantology and Artificial Organs earlier. The patient was transported by air ambulance escorted by the resuscitation team to the Shumakov Federal Research Center of Transplantology and Artificial Organs on 02.05.2023 with negative PCR COVID-19 test. The literature data on the frequency of association of these diseases, clinical features, criteria for diagnosis and treatment, indications for lung transplantation are presented.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1089-1095"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Combined echinococcosis of the lungs, heart and liver: clinic, diagnosis and treatment. Case report]. 肺、心、肝合并棘球蚴病:临床、诊断与治疗。病例报告)。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-12-16 DOI: 10.26442/00403660.2024.11.202998
E V Reznik, M D Iarovoi, S А Zavialova, S M Umakhanova, A S Grigorievskaya, O I Makolin, I V Semeniakin
{"title":"[Combined echinococcosis of the lungs, heart and liver: clinic, diagnosis and treatment. Case report].","authors":"E V Reznik, M D Iarovoi, S А Zavialova, S M Umakhanova, A S Grigorievskaya, O I Makolin, I V Semeniakin","doi":"10.26442/00403660.2024.11.202998","DOIUrl":"10.26442/00403660.2024.11.202998","url":null,"abstract":"<p><p>Echinococcosis or hidatid disease is a parasitic illness which is caused by the most common pathogens <i>Echinococcus granulosus</i>, <i>E. multilocularis </i>and <i>E. oligarthrus</i>. When the agent gets into the organism, it penetrates the organ and forms a cyst. Cysts are located more often (75%) in the liver where they exist without any clinical manifestation. They can be located in other internal organs: lungs, the heart and others. The localization of cysts in several organs simultaneously is a very rare case. The article aims to demonstrate a patient who had a combined echinococcosis of the lungs, heart and liver.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 11","pages":"1097-1103"},"PeriodicalIF":0.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evaluation of the results of magnetic resonance imaging of the brain for cognitive impairment in patients with heart failure: A review]. [心力衰竭患者认知障碍的脑磁共振成像结果评估:综述]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202853
M A Shariya, D V Ustyuzhanin, I V Zhirov, Y F Osmolovskaya, S N Tereshchenko
{"title":"[Evaluation of the results of magnetic resonance imaging of the brain for cognitive impairment in patients with heart failure: A review].","authors":"M A Shariya, D V Ustyuzhanin, I V Zhirov, Y F Osmolovskaya, S N Tereshchenko","doi":"10.26442/00403660.2024.09.202853","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202853","url":null,"abstract":"<p><p>Cognitive impairment is a very common comorbidity in patients with heart failure (HF). Patients with HF show signs of memory decline, difficulty concentrating, and attention deficits. Cognitive dysfunction in HF is associated with a poor prognosis. However, the diagnosis of cognitive impairment in heart failure has received insufficient attention in routine clinical practice. Neuropsychological screening tests are available to screen for cognitive impairment, but they are used infrequently. Therefore, it is of practical interest to search for magnetic resonance equivalents of cognitive disorders. The use of magnetic resonance imaging as a tool for identifying and quantifying neural correlates of cognitive functions is discussed.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"909-913"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Polymorphism of RAAS genes in patients with COVID-19: comparison with frequency in population and relationship with severity of course]. [COVID-19患者RAAS基因的多态性:与人群频率的比较及与病程严重程度的关系]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202849
A E Bragina, Y N Rodionova, E S Ogibenina, A S Fomin, V I Podzolkov
{"title":"[Polymorphism of RAAS genes in patients with COVID-19: comparison with frequency in population and relationship with severity of course].","authors":"A E Bragina, Y N Rodionova, E S Ogibenina, A S Fomin, V I Podzolkov","doi":"10.26442/00403660.2024.09.202849","DOIUrl":"10.26442/00403660.2024.09.202849","url":null,"abstract":"<p><strong>Aim: </strong>Evaluation of genes polymorphisms frequencies of angiotensinogen (AGT), angiotensin converting enzyme type 1 (ACE1) and angiotensin II receptors type 1 (AGTR1) and type 2 (AGTR2) in patients admitted with coronavirus disease (COVID-19) and its association the severity of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2).</p><p><strong>Materials and methods: </strong>The study included 100 patients admitted to the hospital with a laboratory-confirmed diagnosis of COVID-19. All patients were identified with alleles and genotypes of polymorphic markers rs4762 of the AGT gene, rs1799752 of the ACE1 gene, rs5186 of the AGTR1 gene and rs1403543 of the AGTR2 gene. The frequencies of each polymorphisms were compared with population. Statistical processing was performed using the Statistica 8.0 software package.</p><p><strong>Results: </strong>In evaluated cohort there was higher frequency of D-allele ACE1 rs1799752 compared to population. Depending on the availability of criteria for the severity of coronavirus infection, 44 (44%) patients were diagnosed with severe, 56 (56%) with moderate course. The groups did not significantly differ in age, gender, cardiovascular risk factors and comorbid pathology. In the groups with severe and moderate course, the same distribution of genotypes and alleles of AGT rs4762, AGTR2 rs1403543 and ACE1 rs1799752 was revealed. For the I/D alleles of the ACE1 rs1799752 gene, a significant deviation from the papulation was found in both the group of severe and moderate COVID-19. In the group with a severe course of the disease, a higher frequency of the mutant C-allele of the AGTR1 rs5186 gene was detected. In the same group, a deviation in the frequency ratio of A and C of the AGTR1 rs5186 alleles from Hardy-Weinberg Equilibrium was found. When calculating the risk of severe COVID-19 in the presence of the C-allele compared with the A-allele, an odds ratio 2.092 (95% confidence interval 1.066-4.108) was obtained.</p><p><strong>Conclusion: </strong>The data obtained suggest that the genes polymorphisms of the components of renin-angiotensin-aldosterone system, namely D-allele of ACE1 rs1799752 and C-allele of AGTR1 rs5186, may make it possible to identify groups of patients predisposed to the development of more severe COVID-19.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"872-878"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Biomarkers in acute coronary syndromes: from the origins to the present]. [急性冠状动脉综合征的生物标志物:从起源到现在]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202854
E A Okisheva, O I Trushina
{"title":"[Biomarkers in acute coronary syndromes: from the origins to the present].","authors":"E A Okisheva, O I Trushina","doi":"10.26442/00403660.2024.09.202854","DOIUrl":"10.26442/00403660.2024.09.202854","url":null,"abstract":"<p><p>Acute coronary syndrome remains the leading cause of death in both patients with coronary artery disease and patients with other diseases (such as diabetes mellitus, chronic kidney disease, inflammatory diseases of various etiologies, and others). Early diagnosis of cardiomyocyte damage and necrosis opens up wide opportunities to improve the prognosis of patients with atherosclerotic lesions of the coronary arteries, and also makes it possible to discharge patients without acute cardiovascular pathology from intensive care units with a high degree of probability. The article discusses the evolution of the research and introduction into broad clinical practice of markers of myocardial damage and necrosis, which have largely improved modern clinical practice.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"914-918"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Metabolic disorders in patients with chronic thromboembolic pulmonary hypertension]. [慢性血栓栓塞性肺动脉高压患者的代谢紊乱]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202850
S Y Yarovoy, N M Danilov, G V Shchelkova, E O Dinevich, A A Mitrofanova, I E Chazova
{"title":"[Metabolic disorders in patients with chronic thromboembolic pulmonary hypertension].","authors":"S Y Yarovoy, N M Danilov, G V Shchelkova, E O Dinevich, A A Mitrofanova, I E Chazova","doi":"10.26442/00403660.2024.09.202850","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202850","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the relationship between metabolic disorders and obesity with hemodynamic parameters and the severity of the condition of patients with chronic thromboembolic pulmonary hypertension (CTEPH) based on the POLET register.</p><p><strong>Materials and methods: </strong>The study included patients with CTEPH from the POLET register. Data from medical history, lipid profile, glycemia, uric acid level, weight, height, functional class (FC), distance in the 6-minute walk test (6MWT), echocardiography, and right heart catheterization were used for analysis.</p><p><strong>Results: </strong>The study included 84 patients 60±14 years old, including 45 men. The majority of patients had FC III - 51 (65%), which corresponded to 6MWT - 338±113 m. Nineteen (23%) people had experience in taking PAH specific therapy, 37 (46%) had cardiovascular comorbidity. In the general group, the body mass index (BMI) was 25.7±4.5 kg/m<sup>2</sup>, and normal glycemia, lipid profile, and uric acid levels were also determined. mPAP was 51±12 mmHg, RA area was 25.5 (20; 30) cm<sup>2</sup>. Correlations were identified between: RA area and the level of total cholesterol (r=0.60; <i>p</i><0.01), triglycerides (r=-0.24; <i>p</i><0.001), LDL cholesterol (r=0.75; <i>p</i><i>=</i>0.04), uric acid (r=0.75; <i>p</i>=0.03); total cholesterol and 6MWT (r=0.44; <i>p</i>=0.04). Analysis of metabolic disorders, FC and comorbidity revealed differences between FC III and IV groups in the level of HDL cholesterol (<i>p</i>=0.02) and triglycerides (<i>p</i><0.01).</p><p><strong>Conclusion: </strong>The POLET registry includes mainly older patients. Severe FC (87% - III and IV) may be a result of the older age and the presence of concomitant pathology in almost half of the patients. The discovered relationships between the area of RA and FC with lipid and purine metabolism were discovered for the first time, however, they correspond to the direction of the world scientific researches, are important due to the use of these indicators in the scale for calculating the risk of death in patients with PAH and require further development.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"879-884"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report]. [致病性 TTN 突变患者左心室反向重塑的临床病例。病例报告]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202852
S N Nasonova, A N Meshkov, I V Zhirov, Y F Osmolovskaya, A A Shoshina, A V Gagloev, I H Dzhumaniiazova, E A Zelenova, V V Erema, M S Gusakova, M V Ivanov, M V Terekhov, D A Kashtanova, A I Nekrasova, S I Mitrofanov, A S Shingaliev, V S Yudin, A A Keskinov, N V Gomyranova, U V Chubykina, M V Ezhov, S N Tereshchenko, S M Yudin, S A Boytsov
{"title":"[A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report].","authors":"S N Nasonova, A N Meshkov, I V Zhirov, Y F Osmolovskaya, A A Shoshina, A V Gagloev, I H Dzhumaniiazova, E A Zelenova, V V Erema, M S Gusakova, M V Ivanov, M V Terekhov, D A Kashtanova, A I Nekrasova, S I Mitrofanov, A S Shingaliev, V S Yudin, A A Keskinov, N V Gomyranova, U V Chubykina, M V Ezhov, S N Tereshchenko, S M Yudin, S A Boytsov","doi":"10.26442/00403660.2024.09.202852","DOIUrl":"10.26442/00403660.2024.09.202852","url":null,"abstract":"<p><p>Dilated cardiomyopathy (DCM) is a leading cause of heart failure, sudden cardiac death, and heart transplantation in young patients. The causes of DCM are varied and include genetic factors and metabolic, infectious, toxic and others factors. Today it is known that germline mutations in more than 98 genes can be associated with the occurrence of DCM. However, the penetrance of these genes often depends on a combination of factors, including modifiable ones, i.e. those that change under the influence of the environment. About 20-25% of genetically determined forms of DCM are due to mutations in the titin gene (<i>TTN</i>). Titin is the largest protein in the body, which is an important component of the sarcomer. Although titin is the largest protein in the human body, its role in the physiology of heart and disease is not yet fully understood. However, a mutation in the <i>TTN</i> gene may later represent a potential therapeutic target for genetic and acquired cardiomyopathy. Thus, the analysis of clinical cases of cardiomyopathy in patients with identified mutations in the <i>TTN</i> gene is of great scientific interest. The article presents a clinical case of manifestation of DCM in patient with a revealed pathogenic variant of mutation in the gene <i>TTN</i> and reverse left ventricular remodeling of the against the background of optimal therapy of heart failure in a subsequent outpatient observation.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"901-908"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Patient selection for left ventricular assist device implantation. The main problems]. [左心室辅助装置植入术的患者选择。主要问题]。
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202851
O Y Narusov, J A Shahramanova, V A Amanatova, A V Sychev, Y F Osmolovskaya, K G Ganaev, A A Shiryaev, I A Merkulova, D V Pevzner, M I Makeev, M A Saidova, F N Paleev, R S Akchurin, S N Tereshchenko, S A Boytsov
{"title":"[Patient selection for left ventricular assist device implantation. The main problems].","authors":"O Y Narusov, J A Shahramanova, V A Amanatova, A V Sychev, Y F Osmolovskaya, K G Ganaev, A A Shiryaev, I A Merkulova, D V Pevzner, M I Makeev, M A Saidova, F N Paleev, R S Akchurin, S N Tereshchenko, S A Boytsov","doi":"10.26442/00403660.2024.09.202851","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202851","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the experience of Chazov National Medical Research Center of Cardiology in patient selection for left ventricular assist device (LVAD) implantation.</p><p><strong>Materials and methods: </strong>901 patients, whose documents were sent to Chazov National Medical Research Center of Cardiology from regional medical and prophylactic institutions, were screened as selection for LVAD implantation. Firstly, all patients underwent transthoracic echocardiography performed according to the extended protocol with a comprehensive assessment of the left and right ventricle size and function. Patients who underwent the screening procedure underwent further examination including both laboratory and instrumental diagnostic methods. In addition, the polyclinic database of patients diagnosed with chronic heart failure (CHF) and dilated cardiomyopathy was also analyzed.</p><p><strong>Results: </strong>Among 901 screened patients 7.9% were suitable candidates for LVAD implantation and only 23 (2.6%) patients underwent surgery. Among those not eligible for surgery: 208 (29%) patients were not on optimal medical therapy, 15% of patients had indications for other surgical treatment of CHF, 12% of patients had severe right ventricular failure, 9.8% had severe comorbidities, 6.8% of patients refused surgery.</p><p><strong>Conclusions: </strong>The main problems of selection for LVAD implantation were: low awareness of doctors about the introduction of new treatment methods, poor quality of transthoracic echocardiography, a large percentage of patients not receiving basic therapy for CHF, untimely referral of patients for other types of surgical treatment.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"885-891"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019-2022)]. [真实临床实践中动脉高血压和伴随疾病患者的抗高血压治疗(根据国家动脉高血压登记处,2019-2022 年)】。]
IF 0.3 4区 医学
Terapevticheskii Arkhiv Pub Date : 2024-10-10 DOI: 10.26442/00403660.2024.09.202848
A V Aksenova, E V Oschepkova, I E Chazova
{"title":"[Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019-2022)].","authors":"A V Aksenova, E V Oschepkova, I E Chazova","doi":"10.26442/00403660.2024.09.202848","DOIUrl":"https://doi.org/10.26442/00403660.2024.09.202848","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;Analyze the real ongoing antihypertensive therapy, including the PCT; international nonproprietary names of drugs and their dosages in RCP; compliance of therapy with clinical recommendations; changing trends in the PCT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;An analysis was carried out of the data from the register of AH, the compliance of treatment in different clinical groups of patients and the achievement of BP and low-density lipoprotein cholesterol targets in the sample of 2019-2022 (&lt;i&gt;n&lt;/i&gt;=5012). The prescription of AHD and achievement of targets values were assessed in accordance with current clinical guidelines for the management of AH and hypercholesterolemia. Data from 2010 (&lt;i&gt;n&lt;/i&gt;=7782) and 2020 (&lt;i&gt;n&lt;/i&gt;=3061) were analyzed to assess the dynamics of prescription of monotherapy and PCT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The greatest increase in the number of AHD was observed in patients with hypertension in combination with coronary heart disease, heart failure, and atrial fibrillation. In a small group of patients with hypertension without other CVDs, the recommended combinations of AHD were not prescribed; preference was given to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-adrenoblocker (β-AB). PCT mainly differed from the recommended combinations by the wider use of drugs from the β-AB group. The PCT of recommended drugs was highest in patients with hypertension and coronary artery disease - more than 90%, hypertension and heart failure in 56.2%, hypertension and atrial fibrillation - 33.3%, hypertension and chronic kidney desease - 19.6%. Achievement of BP and low-density lipoprotein cholesterol targets was insufficient in all analyzed groups. Among the international nonproprietary names of drugs, the most frequently prescribed are the following: bisoprolol, metoprolol, lisinopril, perindopril, losartan, spironolactone, amlodipine, torasemide, indapamide, hypochlorothiazide, moxonidine. The prescribed daily dosages were closer to the initial recommended ones. By 2020, the prescription of PCT with β-AB and a more uniform prescription of various combinations will come to the fore, while PCT in 2010 is characterized by the presence of one ","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"860-871"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信